Literature DB >> 81702

Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection.

A Alberti, S Diana, G H Sculard, A L Eddleston, R Williams.   

Abstract

Antibodies in the serum reacting with antigens on the surface of radiolabelled Dane particles distinct from hepatitis B surface and core antigens (HBsAg and HBcAg) were detected, using a double antibody precipitation assay, in 12 out of 15 patients early in the course of acute type B hepatitis and at the time of disappearance of circulating Dane particles. No such antibody activity was found in 15 of the 16 patients with HBsAg-positive chronic active hepatitis, 13 of whom had complete Dane particles in the serum. In a group of 16 asymptomatic HBsAg carriers (without Dane particles in serum) antibody activity was shown in nine. This demonstration of antibodies precipitating Dane particles may be relevant to the clearance of circulating hepatitis B virions and the termination of infection in acute type B hepatitis. Their absence in all but one of the cases of chronic active hepatitis might explain why the virus infection persists in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 81702      PMCID: PMC1608133          DOI: 10.1136/bmj.2.6144.1056

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  Antibody to hepatitis-B-virus core in man.

Authors:  J H Hoofnagle; R J Gerety; L F Barker
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

2.  DNA polymerase in the core of the human hepatitis B virus candidate.

Authors:  W S Robinson; R L Greenman
Journal:  J Virol       Date:  1974-06       Impact factor: 5.103

3.  Differential distribution of Australia-antigen-associated particles in patients with liver diseases and normal carriers.

Authors:  J O Nielsen; M H Nielsen; P Elling
Journal:  N Engl J Med       Date:  1973-03-08       Impact factor: 91.245

4.  Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention.

Authors:  S Krugman; J P Giles
Journal:  N Engl J Med       Date:  1973-04-12       Impact factor: 91.245

5.  Australia antigen: large-scale purification from human serum and biochemical studies of its proteins.

Authors:  J L Gerin; P V Holland; R H Purcell
Journal:  J Virol       Date:  1971-05       Impact factor: 5.103

6.  T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis b virus infection.

Authors:  A Alberti; G Realdi; F Bortolotti; A M Rigoli
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

7.  Heterogeneity and thermolability of 'e'.

Authors:  A Williams; G Le Bouvier
Journal:  Bibl Haematol       Date:  1976

8.  Immune response to hepatitis B surface antigen.

Authors:  A B Ibrahim; G N Vyas; H A Perkins
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

  8 in total
  28 in total

Review 1.  Nature and display of hepatitis B virus envelope proteins and the humoral immune response.

Authors:  A Alberti; W H Gerlich; K H Heermann; P Pontisso
Journal:  Springer Semin Immunopathol       Date:  1990

Review 2.  Immunological aspects of liver disease.

Authors:  A L Eddleston; P T Donaldson; J E Hegarty; B D Reed
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 3.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 4.  Serological responses to HBV infection.

Authors:  E A Fagan; R Williams
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

Review 5.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

Review 6.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

7.  Cellular immunity to nucleocapsid and pre-S determinants in asymptomatic carriers of hepatitis B virus.

Authors:  S Vento; S H Chen; G Giuliani-Piccari; C J O'Brien; P R Dal Monte; A L Eddleston; C R Howard; R Williams
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

8.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

9.  Cellular immunity to the hepatitis B virion in acute hepatitis type B.

Authors:  G Fattovich; A Alberti; C Crivellaro; P Pontisso; F Noventa; G Realdi
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

10.  Effects of prednisolone/azathioprine in chronic hepatitis B viral infection.

Authors:  I V Weller; M F Bassendine; A K Murray; A Craxi; H C Thomas; S Sherlock
Journal:  Gut       Date:  1982-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.